# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Published in Anesthesia and Analgesia, results from the multi-site trial evaluating End-tidal Control software provide compelli...
Project aims to increase access of advanced imaging techniques for clinicians to help drive improved diagnosis and management o...
Jim Cramer recommends buying Merck (MRK) due to faith in CEO Robert Davis. He advises against Teladoc (TDOC) due to Cathie Wood...
Stifel analyst Rick Wise initiates coverage on GE HealthCare Techs (NASDAQ:GEHC) with a Buy rating and announces Price Targe...
GE Healthcare reported Q2 sales of $4.84 billion. Net income rose to $428 million, and adjusted EPS beat estimates at $1.00. De...
Adjusted EBIT margin* in the range of 15.7% to 16.0%, reflecting an expansion of 60 to 90 basis points versus 2023 Adjusted E...